Ocular Therapeutix (NASDAQ:OCUL) Azioni

OCULAR THERAPEUTIX INC

Ocular Therapeutix

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Ocular Therapeutix Inc

Oculis Holding AG

Oculus Inc

In the latest quarter, 4 analysts provided ratings for Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Ocular Therapeutix and provided 12-month price targets. The average target is $16.5, accompanied by a high estimate of $19.00 and a low estimate of $15.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 10.81%. 
<img src="https://www.benzinga.com/files/images/story/2025/1742335274_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Ocular Therapeutix by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens Capital Markets</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ocular Therapeutix. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Ocular Therapeutix compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Ocular Therapeutix's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Ocular Therapeutix's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OCUL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ocular Therapeutix analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Ocular Therapeutix</h2>
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
<h3>Ocular Therapeutix's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Ocular Therapeutix's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 15.41% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ocular Therapeutix's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -283.27%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -14.5%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Ocular Therapeutix's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -10.21%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Ocular Therapeutix's debt-to-equity ratio is below the industry average at 0.24, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

OCUL

What 4 Analyst Ratings Have To Say About Ocular Therapeutix

RBC Capital analyst Luca Issi initiates coverage on Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Outperform rating and announces Price Target of $17.

News

Price Target

Initiation

RBC Capital Initiates Coverage On Ocular Therapeutix with Outperform Rating, Announces Price Target of $17

Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>), noting the company&#8217;s lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">macular degeneration (wet AMD)</a>.
Axpaxli is the company&#8217;s key value driver and is under evaluation in two phase 3 trials. If positive, these trials could support approval with a product label that enables maintenance treatment with Q6M (every 6 months)-Q12M (every 12 months) dosing, which would represent a significant improvement over current treatment options that offer up to Q2M (every two months)-Q4M (every 4 months) dosing.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44256578/wendys-faces-growth-hurdles-as-ceo-unveils-new-plans-to-revive-brand-says-analyst" rel="noreferrer noopener">Analyst Sees Wendy&#8217;s Playing Catch-Up, Needs Stronger Focus on Tech, Talent &amp; Global Expansion</a>
Ocular Therapeutix has completed randomization in the first wet AMD trial, SOL-1. The company expects topline results for SOL-1 to be available in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42969789/ocular-therapeutix-shares-sol-r-enrollment-progress-and-next-steps-for-axpaxli-in-npdr" rel="noreferrer noopener">fourth quarter of 2025</a>.
The company has enrolled 311 subjects in SOL-R, Ocular&#8217;s second registrational trial of Axpaxli in wet AMD. The company also plans to seek FDA feedback in the first half of 2025 on clinical trial design for Axpaxli in non-proliferative diabetic retinopathy (NPDR).
The analyst Serge Belanger has initiated with a Buy rating <a target="_blank" href="https://www.benzinga.com/quote/OCUL/analyst-ratings" rel="noreferrer noopener">and a price target of $15</a>.
Needham writes that intravitreally injected anti-VEGFs make up the ~$15 billion retinal disease market.
The analyst expects Axpaxli to play a role as a second-line treatment in the ~40% of 1.65 million wet AMD patients treated with anti-VEGFs who fail to adequately respond to anti-VEGFs and/or are dissatisfied with the high number of required IVT injections. Needham expects peak sales of around $1.5 billion based on a 15-20% share of this second-line AMD patient population.
&#8220;We believe Axpaxli&#8217;s product profile and unique pivotal ph 3 program offer substantial advantageous differentiation over other products in development seeking to provide long-term treatment duration,&#8221; Needham writes.
Ocular Therapeutix reported a fourth-quarter loss of 29 cents per share, compared to a consensus of 24 cents, with <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">sales of $17.1 million</a>.
The company expects its cash balance of $392.1 million to fund operations into 2028 without raising<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44073248/ocular-therapeutix-reports-fourth-quarter-and-full-year-2024-results-and-business-highlights" rel="noreferrer noopener"> additional capital</a>.
Price Action: OCUL stock is up 10.10% at $8.42 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44259507/goldman-sachs-gains-confidence-in-market-rebound-upgrades-ge-healthcare-amid-china-recovery-hopes">Goldman Sachs Gains Confidence In Market Rebound, Upgrades GE Healthcare Amid China Recovery Hopes</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Health Care

Movers

Trading Ideas

General

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

WIIM

Ocular Therapeutix shares are trading higher after Needham initiated coverage on the stock with a Buy rating and announced a price target of $15.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keefe, Bruyette &amp; Woods analyst Damon Delmonte initiated coverage on Northpointe Bancshares, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPB#NYSE">NPB</a>) with an Outperform rating and announced a price target of $18. Northpointe Bancshares shares closed at $13.63 on Monday. <a href="https://www.benzinga.com/quote/NPB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Scott Buck initiated coverage on Inuvo, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) with a Buy rating and announced a price target of $2. Inuvo shares closed at $0.3538 on Monday. <a href="https://www.benzinga.com/quote/INUV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Serge Belanger initiated coverage on Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Buy rating and announced a price target of $15. Ocular Therapeutix shares closed at $7.65 on Monday. <a href="https://www.benzinga.com/quote/OCUL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dumoulin-Smith initiated coverage on Primoris Services Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NYSE">PRIM</a>) with a Buy rating and announced a price target of $73. Primoris Services shares closed at $60.51 on Monday. <a href="https://www.benzinga.com/quote/PRIM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jones Trading analyst Justin Walsh initiated coverage on Serina Therapeutics, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SER#AMEX">SER</a>) with a Buy rating and announced a price target of $11. Serina Therapeutics shares closed at $4.78 on Monday. <a href="https://www.benzinga.com/quote/SER/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PRIM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="598" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11082113/image-66-1024x598.png" alt="" class="wp-image-818622" style="width:459px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11082113/image-66-1024x598.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11082113/image-66-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11082113/image-66-768x449.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11082113/image-66.png 1087w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44218016/top-3-financial-stocks-that-may-fall-off-a-cliff-in-march">Top 3 Financial Stocks That May Fall Off A Cliff In March</a></li>
</ul>

Pre-Market Outlook

Markets

INUV

PRIM

This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Needham analyst Serge Belanger initiates coverage on Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Buy rating and announces Price Target of $15.

Needham Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $15

Citizens Capital Markets analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Market Outperform and lowers the price target from $22 to $19.

Citizens Capital Markets Maintains Market Outperform on Ocular Therapeutix, Lowers Price Target to $19

HC Wainwright &amp; Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Buy and maintains $15 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $15 Price Target

Ocular Therapeutix shares are trading lower after the company reported worse-than-expected Q4 financial results.

Guidance

Ocular Therapeutix Expects Cash Balance Of $392.1M As Of December 2024 To Fund Operations Into 2028, Currently Does Not Intend To Raise Additional Capital This Year

Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.24) by 20.83 percent. This is a 17.14 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $17.08 million which missed the analyst consensus estimate of $17.20 million by 0.71 percent. This is a 15.41 percent increase over sales of $14.80 million the same period last year.

Earnings

Earnings Misses

Ocular Therapeutix Q4 2024 GAAP EPS $(0.29) Misses $(0.24) Estimate, Sales $17.08M Miss $17.20M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) is expected to report earnings for its second quarter. 
• TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $99.36 million. 
• Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $274.06 million. 
• Burford Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUR#NYSE">BUR</a>) is projected to report quarterly earnings at $0.59 per share on revenue of $216.00 million. 
• Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $52.70 million. 
• Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) is projected to report quarterly loss at $0.16 per share on revenue of $7.64 million. 
• AG Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $17.01 million. 
• Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) is likely to report quarterly loss at $1.07 per share on revenue of $21.98 million. 
• Nomad Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOMD#NYSE">NOMD</a>) is estimated to report quarterly earnings at $0.38 per share on revenue of $796.56 million. 
• Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) is projected to report quarterly loss at $0.22 per share on revenue of $16.89 million. 
• BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) is expected to report quarterly loss at $0.03 per share on revenue of $22.77 million. 
• Surgery Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) is projected to report quarterly earnings at $0.49 per share on revenue of $828.01 million. 
• N-able (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NABL#NYSE">NABL</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $113.77 million. 
• Ready Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RC#NYSE">RC</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $55.44 million. 
• Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) is likely to report quarterly loss at $0.35 per share on revenue of $25.62 million. 
• Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) is expected to report quarterly loss at $0.06 per share on revenue of $6.42 million. 
• Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) is likely to report quarterly loss at $0.67 per share on revenue of $234.99 million. 
• GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) is likely to report earnings for its fourth quarter. 
• Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $703.90 million. 
• California Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRC#NYSE">CRC</a>) is expected to report quarterly earnings at $1.02 per share on revenue of $904.91 million. 
<h3>Companies Reporting After The Bell</h3>
• NuScale Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $1.07 million. 
• B. Riley Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) is likely to report earnings for its fourth quarter. 
• ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) is projected to report quarterly earnings at $0.16 per share on revenue of $113.40 million. 
• Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) is expected to report quarterly loss at $0.08 per share on revenue of $5.30 million. 
• GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) is projected to report quarterly earnings at $0.88 per share on revenue of $288.33 million. 
• Smart Sand (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SND#NASDAQ">SND</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $65.90 million. 
• OFS Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFS#NASDAQ">OFS</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $10.30 million. 
• Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) is likely to report earnings for its fourth quarter. 
• Crawford &amp; Company Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $334.82 million. 
• MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $726.90 million. 
• W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) is expected to report quarterly loss at $0.25 per share on revenue of $130.04 million. 
• Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) is estimated to report quarterly earnings at $1.08 per share on revenue of $95.23 million. 
• AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) is expected to report quarterly loss at $0.15 per share on revenue of $1.88 million. 
• Ranger Energy Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNGR#NYSE">RNGR</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $142.60 million. 
• James River Gr Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>) is projected to report quarterly loss at $0.46 per share on revenue of $159.91 million. 
• Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) is likely to report quarterly loss at $0.08 per share on revenue of $270.50 million. 
• Repay Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $82.56 million. 
• Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $83.91 million. 
• GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) is expected to report quarterly earnings at $0.23 per share on revenue of $206.48 million. 
• Crawford &amp; Company Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) is projected to report quarterly earnings at $0.24 per share on revenue of $334.82 million. 
• Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) is expected to report quarterly loss at $0.06 per share on revenue of $19.83 million. 
• Intrepid Potash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) is likely to report quarterly loss at $0.05 per share on revenue of $53.44 million. 
• Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) is projected to report quarterly loss at $0.03 per share on revenue of $7.79 million. 
• Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $1.29 million. 
• NCR Atleos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) is estimated to report quarterly earnings at $1.02 per share on revenue of $1.10 billion. 
• Heidrick &amp; Struggles Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSII#NASDAQ">HSII</a>) is expected to report quarterly earnings at $0.63 per share on revenue of $263.33 million. 
• Concentra Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $463.65 million. 
• ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $70.65 million. 
• Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) is expected to report quarterly earnings at $0.74 per share on revenue of $669.10 million. 
• Kayne Anderson BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBDC#NYSE">KBDC</a>) is estimated to report earnings for its fourth quarter. 
• BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) is expected to report quarterly loss at $0.05 per share on revenue of $106.20 million. 
• Whitestone REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSR#NYSE">WSR</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $38.39 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADMA

ASTS

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

BDSX

BLFS

BRCC

DAVE

EKSO

FTRE

GTLB

GUTS

HSII

JRVR

KBDC

MITT

MRSN

NABL

NATL

NOMD

NOVA

OKTA

PLUG

RILY

RNGR

RPAY

SENS

SGRY

SNDX

SPHR

STXS

TDUP

TGTX

Earnings Scheduled For March 3, 2025

Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>, "Ocular", the "Company"))), a biopharmaceutical company committed to redefining the retina experience, outlined exceptional clinical progress across its registrational program for AXPAXLI&#x2122; in wet age-related macular degeneration (wet AMD), plans to advance AXPAXLI in non-proliferative diabetic retinopathy (NPDR), and the Company's strategic outlook for 2025 in its presentation at the 43rd Annual J.P. Morgan Healthcare Conference (JPM 2025).

Ocular Therapeutix Showcases Progress on AXPAXLI for Wet AMD and Diabetic Retinopathy at JPM 2025

<h3>Gainers</h3>
<ul>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares increased by 81.0% to $2.28 during Monday's pre-market session. The company's market cap stands at $9.0 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares moved upwards by 36.93% to $7.6. The company's market cap stands at $464.9 million. </li>
<li>Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) shares rose 35.56% to $128.61. The company's market cap stands at $13.6 billion. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock rose 32.73% to $0.16. The market value of their outstanding shares is at $2.4 million. </li>
<li>CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) stock moved upwards by 27.53% to $3.52. The market value of their outstanding shares is at $40.6 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares increased by 26.03% to $3.34. The market value of their outstanding shares is at $7.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) stock fell 14.7% to $7.0 during Monday's pre-market session. The company's market cap stands at $1.1 billion. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares declined by 13.69% to $0.82. The market value of their outstanding shares is at $9.8 million. </li>
<li>Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) shares decreased by 12.7% to $29.43. The market value of their outstanding shares is at $105.5 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock fell 12.49% to $0.61. The market value of their outstanding shares is at $2.9 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) stock declined by 12.21% to $5.25. The company's market cap stands at $303.8 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) stock declined by 12.11% to $0.71. The market value of their outstanding shares is at $3.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

ALGS

ATPC

GCTK

GDTC

GTBP

INDP

ITCI

NAYA

SAGE

12 Health Care Stocks Moving In Monday's Pre-Market Session

Across the recent three months, 4 analysts have shared their insights on Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $16.5, with a high estimate of $22.00 and a low estimate of $14.00. This current average reflects an increase of 15.14% from the previous average price target of $14.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1733245224_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Ocular Therapeutix. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ocular Therapeutix. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ocular Therapeutix compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Ocular Therapeutix's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ocular Therapeutix's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OCUL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ocular Therapeutix analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Ocular Therapeutix: A Closer Look</h2>
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
<h3>Ocular Therapeutix: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Ocular Therapeutix showcased positive performance, achieving a revenue growth rate of 2.28% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ocular Therapeutix's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -236.58%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Ocular Therapeutix's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -10.0%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Ocular Therapeutix's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.24%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Ocular Therapeutix's debt-to-equity ratio is below the industry average. With a ratio of 0.21, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts

Ocular Therapeutix Announced That More Than 300 Patients Have Been Randomized In SOL-1 Phase 3 Trial For Axpaxli (Axitinib Intravitreal Implant, Or OTX-TKI) For Wet Age-related Macular Degeneration, And The Trial Is Expected To Close Randomization This Week, Topline Data Are Expected In Q4 Of 2025

HC Wainwright &amp; Co. analyst Yi Chen maintains Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Buy and raises the price target from $14 to $15.

HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $15

Ocular Therapeutix's Cash Balance Of $427.2M As Of September 30, 2024, Expected To Fund Operations Into 2028

Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 8.33 percent. The company reported quarterly sales of $15.43 million which missed the analyst consensus estimate of $17.14 million by 10.01 percent. This is a 2.28 percent increase over sales of $15.08 million the same period last year.

Ocular Therapeutix Q3 2024 GAAP EPS $(0.22) Beats $(0.24) Estimate, Sales $15.43M Miss $17.14M Estimate

Press Releases

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Ocular Therapeutix™ to Present at Two Investor Conferences in March

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

Comments

Ocular Therapeutix

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO